Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYMPHONY: AXS-12 in Narcolepsy with Cataplexy and EDS
NCT05059223Phase 3Completed
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Sep 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of reboxetine in narcolepsy, cataplexy, Excessive Daytime Sleepiness (EDS), sponsored by Axsome Therapeutics, Inc.. Started Sep 2021; status: completed.
02
Drugs
reboxetine
03
Conditions
narcolepsycataplexyExcessive Daytime Sleepiness (EDS)
Beyond the preview
Go deeper on NCT05059223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05059223.